Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Emily Reeve, Barbara Farrell, Wade Thompson, Nathan Herrmann, Ingrid Sketris, Parker J Magin, Lynn Chenoweth, Mary Gorman, Lyntara Quirke, Graeme Bethune and Sarah N Hilmer Med J Aust 2019; 210 (4): . || doi: 10.5694/mja2.50015 Published online: 4 March 2019 Topics Abstract Introduction: Cholinesterase inhibitors (ChEIs) and memantine are medications used

Memantine for dementia. Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off-label for mild AD.To determine efficacy and safety of memantine for people with dementia. To assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs).We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register (...) of trials (http://www.medicine.ox.ac.uk/alois/) up to 25 March 2018. We examined clinical trials registries, press releases and posters of memantine manufacturers; and the web sites of the FDA, EMEA and NICE. We contacted authors and companies for missing information.Double-blind, parallel group, placebo-controlled, randomised trials of memantine in people with dementia.We pooled and analysed data from four clinical domains across different aetiologies and severities of dementia and for AD

Memantine Top results for memantine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for memantine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine Developing organisations: The University of Sydney NHMRC Partnership Centre: Dealing with Cognitive and Related Functional Decline in Older People (Cognitive Decline Partnership Centre) Bruyère Research Institute, Deprescribing Guidelines in the Elderly Project Evidence-based clinical practice (...) guideline for deprescribing cholinesterase inhibitors and memantine: 2018 2 © The University of Sydney ISBN Online: 978-0-6482658-0-1 ISBN Print: 978-0-6482658-1-8 Publication date: February 2018 Suggested citation: Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin P, Chenoweth L, Gorman M, Quirke L, Bethune G, Forbes F, Hilmer S. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Sydney: The University of Sydney; 2018. The full guideline

Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta‐Analysis The aim of this work was to utilize meta-analysis in examining the effects of memantine on neuropsychological functioning in patients with Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB).Included studies fulfilled these criteria: included objective cognitive measures, a comparison group of participants not taking memantine, and provided sufficient data for calculation (...) ). Specific neuropsychological domains did not moderate effect size, though. Moderator analysis studies using a mix of DLB and PDD subjects showed larger effects than those that included DLB or PDD patients only. Additionally, open-label trials had significantly (P < 0.001) larger effect sizes (d = 1.32) than placebo-controlled trials (d = 0.12).The present study indicates that effect-size heterogeneity across studies of memantine in DLB and PDD patients is moderated by diagnostic makeup of the cohort

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Several studies have tested the N-methyl-D-aspartate-receptor antagonist memantine as an add-on to pre-existing treatment with acetylcholinesterase inhibitors. The objective of this study was to evaluate the efficacy and safety of a combined memantine and galantamine-CR de novo regimen compared with galantamine-CR only treatment (...) in never treated patients with mild-to-moderate Alzheimer's disease (AD).Antidementia drug-naïve participants (n = 232) with probable, mild-to-moderate AD, and mini-mental state examination scores between 15 and 26 (inclusive) were randomized to receive either 20 mg/day memantine plus 24 mg/day galantamine-CR or 24 mg/day galantamine-CR plus placebo in a 52-week, prospective, double-blind, controlled trial. The primary outcome measurement was the change on the Alzheimer's disease assessment scale

Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up Fibromyalgia (FM) is a prevalent and disabling chronic disease. Recent studies have found elevated levels of glutamate in several brain regions, leading to hypotheses about the usefulness of glutamate-blocking drugs such as memantine in the treatment of FM. The aim of this study was to evaluate the efficacy of memantine in the treatment of pain and other clinical variables (...) (global function, clinical impression, depression, anxiety, quality of life) in FM patients. A double-blind, parallel randomised controlled trial was developed. A total of 63 patients diagnosed with FM were recruited from primary health care centres in Zaragoza, Spain. Memantine was administered at doses of 20mg/d after 1 month of titration. Assessments were carried out at baseline, posttreatment, and 3- and 6-month follow-up. Compared with a placebo group, memantine significantly decreased ratings

Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules U.S. Department of Health and Human Services Search FDA Submit search Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Company: Forest Laboratories, Inc. Application No.: 206439 Approval Date: 12/23/2014

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.Double-blind, placebo-controlled, parallel-group (...) , randomized clinical trial involving 613 patients with mild to moderate AD initiated in August 2007 and concluded in September 2012 at 14 Veterans Affairs medical centers.Participants received either 2000 IU/d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or placebo (n = 152).Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78). Secondary outcomes included cognitive, neuropsychiatric, functional, and caregiver

Balaxur (memantine hydrochloride / donepezil hydrochloride) 18 October 2012 EMA/817438/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Balaxur International non-proprietary name: memantine hydrochloride / donepezil hydrochloride Procedure No. EMEA/H/C/002708 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European (...) Assessment report Page 2/63 IMP Investigational medicinal product IMS-IPD IMS-Prescribing Insights Database ip intraperitoneal IT Italy ITT Intent to treat LC/MS/MS Liquid chromatography with tandem mass spectrometric detection LOCF Last observation carried forward Log Kow octanol-water partition coefficient MADRS Montgomery and åsberg depression rating scale MCID Minimal clinically important difference MDS Minimum data set MEM/DPZ Memantine/ donepezil MMSE Mini mental state examination MoA Mechanism

Nemdatine - memantine London, 21 February 2013 EMA/228869/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nemdatine International non-proprietary name: Memantine Procedure No. EMEA/H/C/002680 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail (...) a Marketing Authorisation to Nemdatine. Assessment report EMA/CHMP/87358/2013 Page 6/19 2. Scientific discussion 2.1. Introduction Nemdatine 5 mg, 10 mg, 15 mg and 20 mg film coated tablets is a generic medicinal product of Ebixa, which has been authorised in the EU since 15 May 2002. The active substance of Nemdatine is memantine hydrochloride, a psychoanaleptic, anti-dementia drug (N06DX01). Memantine is a voltage-dependent, moderate-affinity non-competitive N-methyl-D- aspartate (NMDA) receptor

Marixino (previously Maruxa) - memantine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 17 January 2013 EMA/293975/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Maruxa International non-proprietary name (...) : Memantine Procedure No. EMEA/H/C/002658 Assessment report as adopted by the CHMP with all commercially confidential information deleted Assessment report EMA/293975/2013 Page 2/20 Product information Marketing authorisation application Name of the medicinal product: Maruxa Applicant: Krka d.d. Novo mesto Šmarješka cesta 6 8501 Novo mesto SLOVENIA Active substance: Memantine hydrochloride International Nonproprietary Name: Memantine Pharmaco-therapeutic group (ATC Code): Other anti-dementia drugs(N06DX01

Memantine ratiopharm 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 21 March 2013 EMA/328117/2013 Committee for Medicinal Products for Human Use (CHMP) Memantine ratiopharm memantine Procedure No. EMEA/H/C/002671/0000 Assessment report (...) for initial marketing authorisation application Assessment report as adopted by the CHMP with all commercially confidential information deleted Memantine Ratiopharm CHMP assessment report Page 1/19 Table of contents 1. Background information on the procedure 3 1.1. Submission of the dossier 3 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 5 2.1. Introduction 5 2.2. Quality aspects 5 2.2.1. Introduction 5 2.2.2. Active substance 5 2.2.3. Finished medicinal product 7 2.2.4

Memantine LEK London, 21 February 2013 EMA/227468/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Memantine LEK International non-proprietary name: Memantine Procedure No. EMEA/H/C/002630 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info (...) . Pharmacovigilance 17 3. Benefit-risk balance 17 4. Recommendation 18 Memantine LEK EMA/227468/2013 Page 2/18 List of abbreviations AEs adverse events Al or Alu Aluminium ASMF active substance master file AUC0-t Area under the plasma concentration curve from administration to last observed concentration at time t. AUC0- 8 Area under the plasma concentration curve extrapolated to infinite time BE Bioequivalence BMI body mass index Cmax Maximum plasma concentration CLcr creatinine clearance CHMP or CPMP Committee

Memantine Mylan London, 21 February 2013 EMA/229868/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Memantine Mylan International non-proprietary name: Memantine Procedure No. EMEA/H/C/002660 Assessment Report as adopted by the CHMP with all commercially confidential information removed 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info (...) . Conclusions on the chemical, pharmaceutical and biological aspects 11 2.3. Non-clinical aspects 11 2.3.1. Introduction 11 2.3.2. Ecotoxicity/environmental risk assessment 12 2.3.3. Discussion on non-clinical aspects 12 2.3.4. Conclusion on the non-clinical aspects 12 2.4. Clinical aspects 12 2.5. Pharmacovigilance 19 3. Benefit-risk balance 20 4. Recommendation 20 Memantine Mylan EMA/CHMP/91208/2013 Page 2/21 List of abbreviations AAS Atomic Absorption Spectrometry AP Applicant’s Part API Active

Memantine Accord 19 September 2013 EMA/610378/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Memantine Accord International non-proprietary name: memantine Procedure No. EMEA/H/C/002766 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail (...) on the procedure 1.1. Submission of the dossier The applicant Accord Healthcare Limited submitted on 3 September 2012 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Memantine Accord, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a Centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 21 June 2012. The application concerns a generic medicinal product as defined

Acrescent (memantine hydrochloride / donepezil hydrochloride) 18 October 2012 EMA/111381/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Acrescent International non-proprietary name: memantine hydrochloride / donepezil hydrochloride Procedure No. EMEA/H/C/002424 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European (...) Assessment report Page 2/63 IMP Investigational medicinal product IMS-IPD IMS-Prescribing Insights Database ip intraperitoneal IT Italy ITT Intent to treat LC/MS/MS Liquid chromatography with tandem mass spectrometric detection LOCF Last observation carried forward Log Kow octanol-water partition coefficient MADRS Montgomery and åsberg depression rating scale MCID Minimal clinically important difference MDS Minimum data set MEM/DPZ Memantine/ donepezil MMSE Mini mental state examination MoA Mechanism

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer`s disease: systematic review and economic model in 2007 the National Institute of Health and Clinical Excellence (NICE) restricted the use of acetylcholinesterase inhibitors and memantine.we conducted a health technology assessment (HTA) of the effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of AD to re (...) and dead. The perspective was NHS and Personal Social Services and the cost year 2009.confidence about the size and statistical significance of the estimates of effect of galantamine, rivastigmine and memantine improved on function and global impact in particular. Cost-effectiveness also changed. For donepezil, galantamine and rivastigmine, the incremental cost per quality-adjusted life year (QALY) in 2004 was above £50,000; in 2010 the same drugs 'dominated' best supportive care (improved clinical

Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor (...) name or password? You are here Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Article Text Therapeutics Randomised controlled trial Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Pierre N Tariot Statistics

Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. 22711111 2012 08 20 2013 04 17 1539-3704 156 12 2012 Jun 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. JC6-10 10.7326/0003-4819-156-12-201206190-02010 Burke David D St. Vincent's Health Network, Sydney, New South Wales, Australia. eng Comment Journal Article United States Ann Intern Med